COVID-19 Vaccine Updates | Tampa General Hospital

COVID-19 Vaccine Updates

PEDIATRIC VACCINES

As of Saturday, June 18, 2022, the CDC recommends COVID-19 vaccines for everyone 6 months and older in addition to boosters for everyone 5 years and older, if eligible. Use the CDC’s COVID-19 booster tool to learn if and when your child or teen can get boosters to stay up to date with their COVID-19 vaccines.

This is another important step forward in the fight against COVID-19 and it provides increased protection for millions of children and adults in America at risk of being infected by the virus.

Under the CDC’s recommendation:

  • Children ages 6 months to 4 years old receive a three-dose primary series of the Pfizer-BioNTech COVID-19 vaccine or a two-dose Moderna primary series COVID-19 vaccine.

  • Children ages 5 through teenagers 17 years old receive a two-dose primary series of the Pfizer-BioNTech COVID-19 vaccine or a two-dose Moderna primary series COVID-19 vaccine.

  • COVID-19 dosage is based on age on the day of vaccination, not or size or weight.

For more information on vaccination dosage and safety, visit the CDC’s updated COVID-19 Vaccines for Children and Teens webpage.  

At this time, Tampa General Hospital is only offering the Pfizer vaccine to patients 6 months to 17 years of age.

Available COVID-19 vaccination locations for children 6 months and older:

  • TGMG Riverview – 10647 Big Bend Road, Riverview, FL 33578

  • Pediatric Center at Healthpark – 5802 N. 30th Street, Tampa, FL 33610

Schedule a COVID-19 Vaccination Appointment Today

Scheduling for COVID-19 vaccinations can be made through your MyChart account or by calling the TGMG central scheduling line at 813-844-8410. Due to heavy call volume and wait times, please schedule through MyChart if possible.

IMMUNOCOMPRIMISED PATIENTS VACCINES

The Centers for Disease Control and Prevention (CDC) recommends that people who are moderately to severely immunocompromised receive a booster mRNA COVID-19 vaccine (Pfizer or Moderna) at least 28 days after the completion of the initial vaccine. 

This immunocompromised group includes patients who have:

  • Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection
  • Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.

People who need an additional dose and received either the Pfizer or Moderna vaccine series are recommended to receive a third dose of the same vaccine used. If you are unable to get the same vaccine type as the initial series, you may use the alternative (Moderna or Pfizer).

Find a Vaccine Location Near You

The mRNA COVID-19 primary and booster vaccines are available in local pharmacies, supermarkets, and other community resources. Find a COVID-19 vaccine near you at www.vaccines.gov.

Schedule Your Booster with TGMG

We also offer mRNA COVID-19 vaccines in our TGMG primary care clinics on certain days. Schedule your COVID-19 primary or booster vaccine through your MyChart account. 

Important Info for Transplant Patients

Please contact your transplant coordinator for appropriateness of the COVID-19 vaccine if any of the following apply:

  • If you received an organ transplant in the past 30 days
  • Had a hospital admission in the past 30 days
  • Have been exposed to COVID-19 within the past 48 hours

Important Info for Cancer Patients

Please contact your oncology team for appropriateness of the COVID-19 vaccine if any of the following apply:

  • Acute leukemia patients in active treatment
  • Lymphoma patients receiving anti-CD20 Monoclonal antibodies (rituximab, obinutuzumab, ofatumumab) as part of their treatment

The above group of patients may also benefit with an anti-COVID monoclonal antibodies if recent high risk exposure.

Not sure if you qualify?

Contact your doctor, specialist or transplant coordinator.

To receive a booster vaccine, patients must meet immunocompromoised eligibility as defined by the CDC.